diaDexus, Inc. – ‘8-K’ for 7/2/02 – EX-99.3

On:  Monday, 7/15/02, at 4:35pm ET   ·   For:  7/2/02   ·   Accession #:  1169232-2-143   ·   File #:  0-26483

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                         4     12K 
 2: EX-99.1     Press Release Issued July 2, 2002                      2     10K 
 3: EX-99.2     Amended and Restated License and Supply Agreement     31    120K 
 4: EX-99.3     Press Release Issued July 8, 2002                      2     11K 

EX-99.3   —   Press Release Issued July 8, 2002

EX-99.3
1st Page of 2
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
Exhibit 99.3                                                                    

 VaxGen Hires Former Mercer Consultant
to Head Business Development
Piers Whitehead is Latest in a Series of Prominent Executive Hires

    BRISBANE, Calif. - July 8, 2002 - VaxGen Inc. announced today that Piers
Whitehead, a widely recognized consultant and advisor to the pharmaceutical and 
vaccine industry, has joined the company as Vice President, Corporate and       
Business Development. Whitehead previously served as a senior executive with    
Mercer Management Consulting, where he led a series of marketing, strategy and  
manufacturing projects with an emphasis on global health and vaccines.          

"Piers' reports on the state of international vaccine development,  
including the analysis of manufacturing economics for the developing world, have
become standard references for the field," said Lance K. Gordon, Ph.D., Chief   
Executive Officer of VaxGen. "He is the ideal person to guide the               
commercialization of our AIDS vaccine candidates and lead the company's efforts 
to expand its business through the development of additional biopharmaceutical  
products."                                                                      

   Whitehead is the latest in a series of industry leaders who have joined
VaxGen recently. Earlier this year, VaxGen hired James P. Panek, the former head
of manufacturing operations at Genentech, Inc., as well as Marc Gurwith, M.D.,  
J.D., and Carmen M. Betancourt to head Clinical and Regulatory functions,       
respectively.                                                                   

"I believe VaxGen has a tremendous opportunity to become one of the 
world's leading vaccine companies at a time of rapid growth in the vaccines     
market," Whitehead said. "The vaccines market has been growing 10% annually for 
the past 10 years, and I expect that rate to accelerate, as new products -      
including, we hope, VaxGen's AIDS vaccine candidates - are licensed, and as U.S.
government funding for bio-defense vaccines increases. The coming new generation
of vaccines hold extraordinary promise for public health and a significant      
market opportunity for VaxGen."                                                 

     Whitehead's duties will include business development for Celltrion, Inc.,
VaxGen's joint-venture to build cGMP biopharmaceutical manufacturing facilities.
Whitehead will be charged with establishing business relationships with         
biopharmaceutical companies interested in manufacturing products at Celltrion,  
which is 44% owned by VaxGen.                                                   

   Whitehead served most recently as a Vice President and head of Mercer's
San Francisco office, where he led marketing and business development           
activities. Whitehead joined Mercer in 1991 in the firm's London office.        
Previously, he served as a research analyst for Strategic Planning Associates   
and Robert Fleming Securities Ltd. in London.                                   

EX-99.3
Last Page of 2
TOC
1st
Previous
Next
↓Bottom
Just 2nd
   Whitehead earned his master's and bachelor's degrees, both with honors,
from Oriel College, Oxford, England.                                            

About VaxGen                                                                    

    VaxGen is focused on the commercial development of biologic products for
the prevention and treatment of human infectious diseases and is the only       
company with AIDS vaccine candidates in Phase III clinical trials. VaxGen's two 
trials, involving nearly 8,000 volunteers in North America, Europe and Thailand,
are designed to determine if VaxGen's AIDSVAX investigational vaccine can       
prevent humans from becoming infected with HIV, the virus that causes AIDS.     
VaxGen expects to announce primary results from the first trial in the first    
quarter of 2003, with results from the second trial expected about nine months  
later.                                                                          

VaxGen is also the largest shareholder of Celltrion, Inc., a company
created to provide manufacturing services, principally for products produced in 
mammalian cell culture, including AIDSVAX. VaxGen is located in Brisbane, Calif.
For more information, please visit the company's web site at: www.vaxgen.com.   
AIDSVAX(R)is a registered trademark of VaxGen.                                  

     Note: This press release contains "forward-looking statements" within the
meaning of the federal securities laws. These forward-looking statements include
without limitation statements regarding the progress, costs and results of our  
Phase III clinical trials; domestic and foreign regulatory approvals of AIDSVAX;
the growth rate of the vaccine industry and vaccines markets; the ability to    
manufacture AIDSVAX; our ability to commercialize AIDSVAX and strike marketing, 
manufacturing and other business partnerships; our ability to manage our foreign
manufacturing joint venture; the timing and announcement of results of either of
our Phase III clinical trials; and our beliefs regarding the future success of  
AIDSVAX and other products currently under development or proposed to be        
developed. These statements are subject to risks and uncertainties that could   
cause actual results and events to differ materially from those anticipated.    
Reference should be made to VaxGen's Quarterly Report on Form 10-Q, filed with  
the Securities and Exchange Commission on May 15, 2002, under the heading "Risk 
Factors," and to VaxGen's Annual Report on Form 10-K, filed with the Securities 
and Exchange Commission on April 1, 2002, under the heading "Business" for a    
more detailed description of such factors. Readers are cautioned not to place   
undue reliance on these forward-looking statements that speak only as of the    
date of this release. VaxGen undertakes no obligation to update publicly any    
forward-looking statements to reflect new information, events, or circumstances 
after the date of this release or to reflect the occurrence of anticipated      
events.                                                                         

Dates Referenced Herein   and   Documents Incorporated by Reference

				Referenced-On Page
This ‘8-K’ Filing		Date		First		Last			Other Filings
Filed on:		7/15/02
		7/8/02		1
For Period End:		7/2/02
		5/15/02		2					10-Q
		4/1/02		2					10-K
									List all Filings